Is CELG a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

6,537 people get CELG articles and Market Currents by email alert.

Get email alerts on CELG »

HEADLINES:

Celgene's Management Presents at 2013 UBS Global Healthcare Conference (Transcript)
Wed, May 22
Celgene: Apremilast For Psoriatic Arthritis Offers Upside
Todd Campbell • Tue, May 14 • 2 Comments
Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 4 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived
The Progressive • Thu, May 9 • 60 Comments
Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13)
SA Editor Miriam Metzinger • Sun, May 5 • 4 Comments
Biotechnology: Strong Fundamentals Are The Basis Of Strong Performance
Ryan's View • Fri, May 3 • 5 Comments
Biotech Bulls Can Ignore The Warning Signs At Their Peril
EP Vantage • Thu, May 2 • 7 Comments
Celgene Corporation to Webcast at Upcoming Investor Conferences and Analyst Day

Business Wire (Apr 29, 2013)
Cramer's Mad Money - 16 Things To Watch In The Week Ahead (4/26/13)
SA Editor Miriam Metzinger • Sun, Apr 28 • 5 Comments
Cramer's Mad Money - Sinclair's Remarkable Transformation (4/26/13)
SA Editor Miriam Metzinger • Sun, Apr 28
Cramer's Mad Money - Why Analysts Were Wrong About Microsoft (4/25/13)
SA Editor Miriam Metzinger • Fri, Apr 26 • 11 Comments
Celgene's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25
Celgene: Going Higher And Higher
Albert Podell • Thu, Apr 25 • 27 Comments
Celgene Reports First Quarter 2013 Operating and Financial Results

Business Wire (Apr 25, 2013)
Cramer's Mad Money - National Lemming Day (4/24/13)
SA Editor Miriam Metzinger • Thu, Apr 25
Investors May Want To Fade Healthcare In May
Todd Campbell • Wed, Apr 24 • 5 Comments
Threshold: My Biotech Pick Of The Year
Equity Options Guru • Tue, Apr 23 • 14 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Tue, Apr 23 • 1 Comment
Cramer's Mad Money - Analysts Keep Beating Dead Horses (4/17/13)
SA Editor Miriam Metzinger • Thu, Apr 18 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

Celgene: Apremilast For Psoriatic Arthritis Offers Upside
Todd Campbell • Tue, May 14 • 2 Comments
Celgene: Going Higher And Higher
Albert Podell • Thu, Apr 25 • 27 Comments
Is Celgene's Apremilast A Potential Blockbuster Or Not?
Peter Geschek • Thu, Apr 11 • 3 Comments
Celgene Could Be Turbocharged With 2 Blockbusters: Revlimid And Apremilast
Nick Chiu • Mon, Apr 8
Cyclacel Settles With Celgene, Sacrifices Small Gains For Bigger Interests
Veziris Ventures • Thu, Apr 4 • 8 Comments
Celgene's Rich Pipeline Offers Growth
Todd Campbell • Wed, Apr 3 • 5 Comments
Celgene's Star Drug Revlimid And Its Competitors
Peter Geschek • Sat, Mar 30 • 1 Comment
Celgene: The Biopharma Stock You Need In Your Portfolio
Darius Samz • Thu, Mar 14 • 1 Comment
Celgene: Phenomenal Guidance For This Bio Stock
StockRiters • Mon, Mar 4
Does Celgene Have More Room To Run In 2013?
Claude McQuarrie • Tue, Feb 19 • 10 Comments
Celgene And The Race To Cure Multiple Myeloma
Peter Geschek • Fri, Feb 15 • 3 Comments
Celgene 2017 Guidance: 2 Times 2013 Revenue
William Meyers • Sun, Jan 27 • 3 Comments
Whisper Number Impact: Earnings Preview For Celgene
WhisperNumber • Wed, Jan 23 • 2 Comments
A Look At Celgene's Long-Term Growth
ONeil Trader • Wed, Jan 23 • 2 Comments
Celgene's Stock Runs On A Strong Pipeline Of Drugs And Projected Sales
Glen S. Woods • Wed, Jan 23 • 1 Comment
Celgene Earnings: What To Watch For
Wall Street Trading • Wed, Jan 23 • 1 Comment
Celgene's Long-Term Plan For Generating Blockbusters
Peter Geschek • Mon, Jan 14 • 4 Comments
Celgene Moves Up After Upbeat Forecasts
Brian L. Wilson • Wed, Jan 9 • 2 Comments
Top Bullish Stock On Tuesday: Celgene With Unusual Call Activities
Nick Chiu • Tue, Jan 8 • 10 Comments
Celgene Offers Stable Revenue And A Solid Product Portfolio
Equity Watch • Tue, Dec 18, 2012 • 2 Comments

Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 4 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived
The Progressive • Thu, May 9 • 60 Comments
Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13)
SA Editor Miriam Metzinger • Sun, May 5 • 4 Comments
Biotechnology: Strong Fundamentals Are The Basis Of Strong Performance
Ryan's View • Fri, May 3 • 5 Comments
Biotech Bulls Can Ignore The Warning Signs At Their Peril
EP Vantage • Thu, May 2 • 7 Comments
Cramer's Mad Money - 16 Things To Watch In The Week Ahead (4/26/13)
SA Editor Miriam Metzinger • Sun, Apr 28 • 5 Comments
Cramer's Mad Money - Sinclair's Remarkable Transformation (4/26/13)
SA Editor Miriam Metzinger • Sun, Apr 28
Cramer's Mad Money - Why Analysts Were Wrong About Microsoft (4/25/13)
SA Editor Miriam Metzinger • Fri, Apr 26 • 11 Comments
Cramer's Mad Money - National Lemming Day (4/24/13)
SA Editor Miriam Metzinger • Thu, Apr 25
Investors May Want To Fade Healthcare In May
Todd Campbell • Wed, Apr 24 • 5 Comments
Threshold: My Biotech Pick Of The Year
Equity Options Guru • Tue, Apr 23 • 14 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Tue, Apr 23 • 1 Comment
Cramer's Mad Money - Analysts Keep Beating Dead Horses (4/17/13)
SA Editor Miriam Metzinger • Thu, Apr 18 • 1 Comment
5 Biotechnology Stocks That Greatly Outperformed The Market In Q1
Brian Nichols • Mon, Apr 15 • 2 Comments
Playing To The Strengths Of Biotech
Richard Cox • Sat, Apr 13 • 6 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Thu, Apr 11 • 1 Comment
Is There No End To The Biotech Bull Market?
Rod Raynovich • Thu, Apr 4 • 3 Comments
Astex Pharmaceuticals: A Catalyst-Driven Year Ahead
PropThink • Thu, Apr 4 • 1 Comment
Market Internals: A Look Beneath The Surface
Greg Feirman • Wed, Apr 3 • 2 Comments

Celgene's Management Presents at 2013 UBS Global Healthcare Conference (Transcript)
Wed, May 22
Celgene's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25
Celgene's CEO Presents at Cowen & Company 33rd Annual Health Care Conference (Transcript)
Tue, Mar 5 • 2 Comments
Celgene Corporation's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Jan 24
Celgene's CEO Presents at 31st Annual JPMorgan Healthcare Conference (Transcript)
Mon, Jan 7 • 1 Comment
Celgene Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Oct 25, 2012
Celgene Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Jul 26, 2012
Celgene's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Thu, Apr 26, 2012
Celgene Management Discusses Q4 2011 Results - Earnings Call Transcript
Thu, Jan 26, 2012 • 1 Comment
Celgene Corporation - Shareholder/Analyst Call
Mon, Dec 12, 2011
Celgene Management Discusses Q3 2011 Results - Earnings Call Transcript
Thu, Oct 27, 2011
Celgene Management Discusses Q2 2011 Results - Earnings Call Transcript
Thu, Jul 28, 2011
Celgene's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Thu, Apr 28, 2011 • 2 Comments
Celgene's CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Jan 27, 2011
Celgene CEO Discusses Q3 2010 Results - Earnings Call Transcript
Thu, Oct 28, 2010
Celgene Q2 2010 Earnings Call Transcript
Fri, Jul 30, 2010
Celgene Q1 2010 Earnings Call Transcript
Fri, Apr 30, 2010
Celgene Corporation Q4 2009 Earnings Call Transcript
Thu, Jan 28, 2010
Celgene Corporation Q3 2009 Earnings Call Transcript
Thu, Oct 22, 2009
Celgene Corporation Q2 2009 Earnings Call Transcript
Thu, Jul 23, 2009

Movers & Shakers: Thursday’s movers: Berkshire hit by S&P downgrade

at MarketWatch.com (Thu, 4:28PM)
Jim Cramer's 5 Investing Sweet Spots

at CNBC.com (May 14, 2013)
Michael Sincere's Long-Term Trader: Why I stopped using stop loss orders

at MarketWatch.com (May 9, 2013)
Does a Rally Still Count if Led by Defensive Stocks?

at Fox Business (May 2, 2013)
Celgene Corporation to Webcast at Upcoming Investor Conferences and Analyst Day

Business Wire (Apr 29, 2013)
Lightning Round: Celgene, Dell & More

at CNBC.com (Apr 26, 2013)
Jim Cramer: 14 Stocks for the Younger Generation

at CNBC.com (Apr 25, 2013)
Celgene Reports First Quarter 2013 Operating and Financial Results

Business Wire (Apr 25, 2013)
Lightning Round: Walter Energy, Sourcefire & More

at CNBC.com (Apr 24, 2013)
Cramer: Sellers Clobbering Stocks Recklessly?

at CNBC.com (Apr 24, 2013)
Movers & Shakers: Wednesday’s movers: Apple closes marginally lower

at MarketWatch.com (Apr 24, 2013)
A Make-or-Break Week Ahead for the Stock Market

at CNBC.com (Apr 20, 2013)
Is This Stock Pullback Different Than The Others?

at CNBC.com (Apr 19, 2013)
Historic Highs Feel Like Distant Memory: Pisani

at CNBC.com (Apr 18, 2013)
Jim Cramer: Can These Companies 'Do No Wrong'

at CNBC.com (Apr 17, 2013)
Cramer: This 'Tipping Point' Great for Stocks

at CNBC.com (Apr 15, 2013)
Some Cancers 'Absolutely' Curable: Celgene CEO

at CNBC.com (Apr 11, 2013)
Celgene Corporation to Announce First Quarter 2013 Results on April 25, 2013

Business Wire (Apr 3, 2013)
Cramer: Will These Stocks Keep Up Their Winning Ways

at CNBC.com (Apr 1, 2013)
Stocks Have Room to Run Despite Robust 1Q

at Fox Business (Apr 1, 2013)

CELG vs. ETF Alternatives

Company Description

Celgene Corporation and its subsidiaries (collectively “we” or “our”) is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. We are dedicated... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
Monday, May 6, 3:09 PM Celgene (CELG +0.5%) says Apremilast achieves statistical significance for its primary endpoint in the first company-sponsored study of psoriatic arthritis patients who had not previously received oral DMARDs. This is the fourth randomized Phase III study of the treatment to show promising results. Last month, Deutsche Bank called the drug a potential "blockbuster" in a note accompanying an upgrade. 2 Comments [Healthcare]
Friday, April 26, 8:53 AM Celgene (CELG) says based on a Phase III trial, the Committee for Medicinal Products for Human Use has recommended REVLIMID for approval regarding the treatment of transfusion-dependent anemia due to MDS when other therapies aren't sufficient or prove inadequate. Shares +.85% premarket after falling marginally Thursday following Q1 results. Comment! [Healthcare]
Thursday, April 25, 8:01 AM More on Celgene (CELG) Q1 earnings: REVLIMD sales +16% Y/Y to $1B, light of consensus of $1.1B. ABRAXANE sales of $123M and VIDAZA of $204M inline. SG&A expenses of $333M, +11.3%. Purchased approximately 4.2M shares at cost of $403M (average price $95.95). FY2013 EPS guidance raised to $5.55-$5.65 from $5.50-$5.60. Shares -0.9% premarket. Conference call at 9 ET. (PR) Comment! [Healthcare, On the Move, Earnings]
Thursday, April 25, 7:30 AM Celgene (CELG): Q1 EPS of $1.37 beats by $0.01. Revenue of $1.46B (+15% Y/Y) misses by $0.01B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, April 25, 12:05 AM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Wednesday, April 24, 5:30 PM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Monday, April 22, 8:02 AM Celgene (CELG) +1.8% premarket as Cantor Fitzgerald reiterates the stock a Buy and raises its price target to $142. Comment! [Healthcare, On the Move]
Friday, April 5, 8:13 AM Celgene (CELG) gets an upgrade from Deutsche Bank to Buy from Hold. The bank says survey data gathered from 100 dermatologists and rheumatologists suggests Apremilast is a "blockbuster." DB raises its price target from $105 to $143. Shares +1.4% premarket. 2 Comments [Healthcare, On the Move]
Thursday, April 4, 9:51 AM Cyclacel (CYCC -2.8%) sells four patents to Celgene (CELG +0.8%) for a onetime payment of $5.5M, effectively resolving pending litigation between the two companies. Cyclacel is now free to get back to focusing "on the development of [its] pipeline," CEO Spiro Rombotis says. Comment! [Healthcare]
Thursday, March 28, 4:24 PM Biotech ETFs close at or near all-time highs as heavyweights Amgen (AMGN +2.4%), Biogen (BIIB +5.2%), Celgene (CELG +2.4%) and Gilead Sciences (GILD +2.5%) make new 52-week highs going into the holiday weekend. 1 Comment [Healthcare]
Monday, March 11, 9:34 AM The National Comprehensive Cancer Network (NCCN) adds the combination of carfilzomib, which is sold by Onyx Pharmaceuticals (ONXX), lendalidomide (made by Celgene (CELG)) and dexamethasone to its guidelines as an option for treating multiple myeloma patients who are also transplant candidates. The NCCN also adds carfilzomib monotherapy and other agents as a preferred treatment regimen for salvage therapy. The FDA hasn't approved carfilzomib for these uses, so Onyx won't market carfilzomib for them. Comment! [Healthcare]
Monday, March 4, 9:37 AM Celgene (CELG) -2.2% as hopes fade that the company's Apremilast anti-inflammatory treatment can become a blockbuster. At the weekend, Celgene released disappointing results for Apremilast from a Phase III trial of patients with psoriasis, an autoimmune skin disease. Comment! [Healthcare]
Sunday, March 3, 9:02 AM Hopes of a blockbuster for Celgene's (CELG) apremalist fade after Phase III results showed just 33% of patients had a 75% reduction in psoriasis vs. 41% in the midstage trial. Management had hoped for $1.1B-$1.75B in peak sales for the drug, a figure few on the Street were buying. (PR) 3 Comments [Healthcare]
Sunday, March 3, 4:02 AM Celgene's (CELG) Apremilast anti-inflammatory treatment reduced the symptoms of psoriasis, an autoimmune skin disease, by 75% in a third of patients in a Phase III trial. However, that's below the 41% rate in a Phase II study, raising doubts about whether Apremilast will meet Celgene's hopes and become a new blockbuster drug. Apremilast would compete with rival medicines from AbbVie (ABBV) and Amgen (AMGN). (PR) Comment! [Healthcare]
Wednesday, February 20, 8:45 AM Celgene (CELG +1.8%) agrees to buy back $600M in stock from an investment bank as part of its repurchase program. So far this year, the company has bought back $385M in shares and has $1.45B remaining in the scheme. Celgene has repurchased $5.05B of stock over the past four years. 1 Comment [Healthcare, On the Move]

TruffelPig
So $BMY is more expensive than $CELG? What a world....
14 hours ago
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Capitalist Bull
Leading growth stocks taking a break while the $ES_F shows no signs of fatigue. http://stks.co/qD73 $NFLX $REGN $SPWR $GOOG $CELG $NSM
May 16, 2:22 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Wall Street Transcript
Celgene Corporation ($CELG) Diversifies Revenue Stream, Sees $1.5 Billion Opportunity in Cancer Drug Abraxane- http://su.pr/1wgenU
Apr 29, 1:32 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Holly Thompson
Celgene $CELG reports Q1 EPS of $1.37 beats by $0.01. Revenue of $1.46B (+15% Y/Y) misses by $0.01B.
Apr 25, 9:12 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

morripm
what happened to $CELG today? is there news I'm not seeing? earnings tomorrow?
Apr 24, 6:14 PM
Reply (4)

• !Report Abuse
View all 4 replies
deonmerwe: $CELG tstrange -nothing came up as reason for sell off in 2x volume.Institutions might know something we dont before earnings?
Apr 25, 3:31 AM
• !Report Abuse
The Aristos: Biotech diving. Can't go up continuously. Will recover but where is the question.
Apr 25, 11:19 AM
• !Report Abuse
Add a reply...

140 characters

Jim Van Meerten
$CELG - 100% Barchart technical buy signals - 8 new highs and up 10.24% in the last month - Relative strength Index 78.63%
Apr 11, 2:16 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Holly Thompson
Celgene $CELG price target raised to $140 from $114 at Jefferies.
Apr 11, 9:50 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Fuinhaz Setups for April 5 2013 | $CELG $FB $FFIV $NIHD $RDWR | SharePlanner http://bit.ly/17gVXmw
Apr 5, 9:07 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Returning Upgrades (3/28/13): $AIZ, $ALGT, $ALNY, $ALV, $ANSS, $APH, $ARII, $BDC, $BMRN, $BOFI, $BRK-B, $CAVM, $CBD, $CBS, $CELG, $CGNX
Apr 1, 9:09 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Clayton Rulli
$CELG still a very interesting chart!
Mar 20, 3:15 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

morripm
what happened to $CELG today? is there news I'm not seeing? earnings tomorrow?
Apr 24, 6:14 PM
Reply (4)

• !Report Abuse
View all 4 replies
deonmerwe: $CELG tstrange -nothing came up as reason for sell off in 2x volume.Institutions might know something we dont before earnings?
Apr 25, 3:31 AM
• !Report Abuse
The Aristos: Biotech diving. Can't go up continuously. Will recover but where is the question.
Apr 25, 11:19 AM
• !Report Abuse
Add a reply...

140 characters

StockBeaver
According to my analysis, $CELG has been overbought since Jan 7th. I like the company... Analysis: http://bit.ly/YkcTGM
Jan 22, 7:16 AM
Reply (4)

• !Report Abuse
View all 4 replies
StockBeaver: I'm working on this feature of allowing users to 'Search'. Two challenges: 1. The site is currently optimized for reads. It's zippy!
Jan 25, 5:20 AM
• !Report Abuse
StockBeaver: The 2nd issue is that any input field on a website is window for hackers. Currently stockbever.com has 0 input fields.
Jan 25, 8:53 AM
• !Report Abuse
Add a reply...

140 characters

Bret Kenwell
Short $CELG
Jan 11, 9:45 AM
Reply (2)

• !Report Abuse
View all 2 replies
21thomas99: Because of the recent run-up?
Jan 11, 6:33 PM
• !Report Abuse
Closet Iguana: good point.
Jan 18, 2:37 AM
• !Report Abuse
Add a reply...

140 characters

Chimera Research Group
$CELG $CELG Abraxane ph 3 pancreatic cancer trial shows stat sig improvemnt in overall survival! Suggested this back in June for subscribrs
11/10/12
Reply (1)

• !Report Abuse
View all 1 replies
Chimera Research Group: See original piece here - http://bit.ly/QvGtG1
11/10/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
CELG Abraxane P3 panc ca studies likely to be a bust. Trial began 3/09; near end of trial 9/11, had to add 210 pts to the study
8/19/12
Reply (2)

• !Report Abuse
View all 2 replies
The Scientist: Only logical reason to add more pts was that OS data was weak; more pts were needed to raise OS data
8/19/12
• !Report Abuse
The Scientist: SPARC recently shown to be beneficial in prostate CA pts.
8/29/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
Awaiting CELG Abraxane data on panc CA. SPARC hypothesis controversial. Abrax does not improve OS in breast CA, which is usually SPARC+.
7/31/12
Reply (2)

• !Report Abuse
View all 2 replies
The Scientist: Perhaps destroying SPARC/stroma promotes metastasis - allows for easier malignant cell escape. Abrax should have worked better in breast CA.
7/31/12
• !Report Abuse
Noreika: Off topic: Did ILNS.PK get halted today? I can't wait to see the Study 301 results!! (the non-carrier one) Or was it the Study 300?
7/31/12
• !Report Abuse
Add a reply...

140 characters

rgide
CELG To Pop after results
7/8/12
Reply (1)

• !Report Abuse
View all 1 replies
maven pharm: I hope you are right
7/8/12
• !Report Abuse
Add a reply...

140 characters

bigazul
CELG got crushed today. Such is the life of a biotech.
6/21/12
Reply (1)

• !Report Abuse
View all 1 replies
blablah: Do not understand the reason for such a big drop. Revlimid's usage is ever increasing and the withdrawal was only for certain strength
6/21/12
• !Report Abuse
Add a reply...

140 characters

Toyman317
CELG is finally showing some signs of life....thanks to Cramer last night.
6/14/12
Reply (1)

• !Report Abuse
View all 1 replies
Toyman317: Up 3%
6/14/12
• !Report Abuse
Add a reply...

140 characters

Marc Chaikin
CELG Down 3 Pre Earnings and Rev. Disappoint - Power Gauge Bullish - Buy Dip
4/26/12
Reply (1)

• !Report Abuse
View all 1 replies
Bill Diehl: Am adding to my positions in CELG today.
4/27/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://stks.co/3Wb3 Premarket losers $FURX $TQNT $TSPT $HERO $AKAM $CROX $CELG $MPEL Gainers $PATK $HTWR $LOGI $REGN $CTXS $SPPI $EQIX $CRUS
4/26/12
Reply (5)

• !Report Abuse
View all 5 replies
Maria Auziliadora: Good job
4/26/12
• !Report Abuse
Maria Auziliadora: That stock will come back though that's m feeling maybe not today!!!
4/26/12
• !Report Abuse
Add a reply...

140 characters

Toyman317
CELG has been on a tear lately...up 3.5% even today. I sold way too early. I just hate it when that happens.
1/20/12
Reply (1)

• !Report Abuse
View all 1 replies
Oceanstats: I feel you pain...sold DANG yesterday after soaring.....soaring even more today! DANG IT!
1/20/12
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD
12/24/11
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man: I agree w/ NVS and STJ. I'd add SNY.
12/25/11
• !Report Abuse
mitrado: $MRK over 37.5 is quite a suicidal choice... it can go up to 50, but it can as easily fall back to 30... :-/
1/19/12
• !Report Abuse
Add a reply...

140 characters

0ZJ
Not a bad day. Consistently beating the indexes at least. Long: AAPL, CELG, DD, ELN, OKS
12/30/11
Reply (4)

• !Report Abuse
View all 4 replies
0ZJ: ...I'm thinking I was at least a day earlier. Per my indicators I could short again today. Comtemplating it.
12/30/11
• !Report Abuse
ker.nulov@gmail.com: I mean, when current month's (high - low) value is inside previous month's (high-low) which usually means that no trend change happened.
12/30/11
• !Report Abuse
Add a reply...

140 characters

0ZJ
Stopped out of DD and CELG for small gain. Stil holding AAPL, close to getting stopped for nice gain from $379. Considering Cyc. Consumer.
12/28/11
Reply (1)

• !Report Abuse
View all 1 replies
0ZJ: Might try a short ETF dependent on what the close says.
12/28/11
• !Report Abuse
Add a reply...

140 characters

CELG Celgene Corporation

CELG

Celgene Corporation